OARS funding Neuroscience

This Small Research Grant Program supports important and innovative research in areas in which more scientific investigation is needed to improve the prevention, diagnosis, treatment and care for Alzheimer's disease and related dementias (AD/ADRD). The program seeks (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neurosciences, AD/ADRD and healthy brain aging, and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

The Alzheimer's Drug Discovery Foundation has issued a Request for Proposals for its Preclinical Drug Discovery program. Through the program, grants of up to $600,000 over two years will be awarded to promising preclinical drug discovery programs relevant to Alzheimer's disease, related dementias, and cognitive aging. Preclinical research funding priorities include high throughput screening, medicinal chemistry hit-to-lead development and optimization, in vitro and in vivo efficacy studies, ADME, toxicology, pharma-cokinetics and pharma-co-dynamics, and in vivo proof-of-concept with lead compounds and biologics. Program areas of particular interest include new chemical compounds for Alzheimer's disease, preclinical proof-of-concept, and re-purposing. With regards to potential drug targets, ADDF is interested in novel targets that include but are not limited to neuro-inflammation, protein degradation/autophagy, growth factor signaling, synaptic function/morphology, calcium regulation, energy utilization/mitochondria function, insulin sensitivity, epigenetics, ApoE function and cholesterol metabolism, vascular injury and the blood-brain barrier interface, cognitive enhancers, myelin changes, ischemia and oxidative stress, and tau-related toxicities. To be eligible, applicants must be academic investigators seeking to create and support innovative translational programs in academic medical centers and universities; biotechnology companies with programs dedicated to Alzheimer's disease translational development; and new biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through program-related investments (PRIs) that require a return on investment based on scientific and/or business milestones.

This Small Research Grant Program supports important and innovative research in areas in which more scientific investigation is needed to improve the prevention, diagnosis, treatment and care for Alzheimer's disease and related dementias. The program seeks to stimulate the next generation of researchers in the United States to pursue research and academic careers in neurosciences, Alzheimer's disease and healthy brain aging.

This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs.

This FOA solicits applications for research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior. The goal is to support projects that can realize a meaningful outcome within 5 years. Applications should address circuit function in the context of specific neural systems such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication or homeostasis. Projects should link theory and data analysis to experimental design and should produce predictive models as deliverables. Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Projects can use non-human and human species, and applications should explain how the selected species offers ideal conditions for revealing general principles about the circuit basis of a specific behavior.

This FOA solicits applications for research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior. The goal is to support projects that can realize a meaningful outcome within 5 years. Applications should address circuit function in the context of specific neural systems such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication or homeostasis. Projects should link theory and data analysis to experimental design and should produce predictive models as deliverables. Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Projects can use non-human and human species, and applications should explain how the selected species offers ideal conditions for revealing general principles about the circuit basis of a specific behavior.

This funding opportunity announcement (FOA) encourages the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, and pharmacodynamic markers that will be utilized to facilitate the development of neurotherapeutics. Ideally, models, model systems and pharmacodynamic markers proposed in applications for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) focused on enabling the exploratory and early stages of drug discovery.

This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs.

To study in vivo synaptic structure and function in Alzheimer's and related dementia; and to advance development of methods to study synapses in animal models and humans.

The Michael J. Fox Foundation works tirelessly to accelerate promising research toward breakthroughs for Parkinson's patients. While our strong emphasis is on funding translational and clinical research, we also support high-risk/high-reward discovery work. In addition to funding, awardees benefit from working with our internal research staff and broad network of scientific and industry advisors. Targeted Funding Opportunities | Application Deadline: May 31, 2018: 1. Alpha-synuclein Biology and Therapies 2. GBA Biology and Therapies 3. Biomarkers of Protein Handling/Autophagy, Exosomes and Lipids 4. Non-Pharmacological Interventions for Gait and Balance Disturbances

The Brain Tumor Funders' Collaborative works to identify potential therapies for patients with primary human brain tumors, with the goal of increasing progression-free patient survival and improving quality of life for patients affected by a primary brain tumor. To that end, BTFC has issued a Request for Proposals for research on the role of the neuro-immune system in the origin and progression of immune responses in primary human brain tumors with the hope of developing immunotherapies for treatment of these tumors in patients. Priority will be given to studies on immune responses in primary brain tumors in pediatric and/or adult human patients. The program, which will provide grants of up to $250,000 per year over three years, will support a small number of multidisciplinary team-based projects. Teams should represent the requisite skills needed to carry out the proposed research, including clinical oncology, tumor biology, neuro-immunology, computational modelling, and data science. Other areas of immunotherapy research may also be entertained, including radiation-induced brain tumors in survivors of childhood cancers who received cranio-spinal radiation for their original cancer (leukemias or medulloblastoma).

The Brain Tumor Funders' Collaborative works to identify potential therapies for patients with primary human brain tumors, with the goal of increasing progression-free patient survival and improving quality of life for patients affected by a primary brain tumor. To that end, BTFC has issued a Request for Proposals for research on the role of the neuro-immune system in the origin and progression of immune responses in primary human brain tumors with the hope of developing immunotherapies for treatment of these tumors in patients. Priority will be given to studies on immune responses in primary brain tumors in pediatric and/or adult human patients. The program, which will provide grants of up to $250,000 per year over three years, will support a small number of multidisciplinary team-based projects. Teams should represent the requisite skills needed to carry out the proposed research, including clinical oncology, tumor biology, neuro-immunology, computational modelling, and data science. Other areas of immunotherapy research may also be entertained, including radiation-induced brain tumors in survivors of childhood cancers who received cranio-spinal radiation for their original cancer (leukemias or medulloblastoma).

CZI Ben Barres Early Career Acceleration Awards: five-year investigator grants for early career academic investigators, with an emphasis on those who are new to the field of neurodegeneration. We seek to empower investigators to pursue bold ideas and to take risks within a supportive and collaborative environment. Awardees will benefit from mentorship support, as well as professional development, training and network opportunities, and practical career guidance to help them navigate this early stage of their careers.

This Funding Opportunity Announcement (FOA) encourages applications for Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research. The NIMH seeks teams of researchers working at different levels of analysis and employing integrative, novel, and creative experimental approaches to address high-risk, high-impact questions in basic neuroscience research, or in translational research with the primary objectives of: (a) advancing the state of the science in basic brain and behavior research that will uncover and dissect the underlying mechanisms that will ultimately provide the foundation for understanding mental disorders; (b) supporting the integration and translation of basic and clinical neuroscience research on severe mental illnesses; and/or (c) advancing our understanding of the neurobehavioral developmental mechanisms and trajectories of psychopathology that begin in childhood and adolescence. The Conte Centers program is intended to support interdisciplinary basic neuroscience or translational research demonstrating an extraordinary level of synergy, integration, and potential for advancing the state of the field. This program is intended only for projects that could not be achieved using other, more standard grant mechanisms. The Conte Centers program also provides an opportunity to establish interdisciplinary basic neuroscience or translational research experiences for students and post doctorates.

The purpose of this funding opportunity announcement (FOA) is to promote initial establishment of basic science-clinical collaborations by providing small grants to teams of basic scientists, physician scientists, and/or clinicians. These interdisciplinary teams may include but are not limited to the following: developmental biologists, cell biologists, geneticists, genomicists, physician scientists including individuals with DVM/VMD degrees, clinicians, epidemiologists, biostatisticians, and/or bioinformaticists. Applications must include at least one scientist with expertise from the basic science side of the spectrum as well as one from the clinical side. The multiple PD/PI model is strongly encouraged but not required. The goal is to facilitate the gathering of preliminary data to support future, larger research grant applications that will combine expertise and integrate basic, translational, and/or clinical approaches to understanding the developmental biology, genetics, and/or environmental basis of structural birth defects.

The Chan Zuckerberg Initiative is inviting applications to join the CZI Neurodegeneration Challenge Network. The goal of this interdisciplinary collaborative initiative is to bring together forward-thinking scientists to work on the challenge of neurodegenerative disorders, with a focus on basic mechanisms in the context of human disease biology.

The New Era of University Innovation & Commercialization This panel discussion examines the future of university and business collaboration, with a focus on inclusive innovation. Thursday, April 19, 2018 from 3:30 PM to 4:45 PM (EDT) Oxford, OH

The Muscular Dystrophy Association is the world's leading nonprofit health agency dedicated to finding treatments and cures for muscular dystrophy, amyotrophic lateral sclerosis (ALS), and other neuromuscular diseases. It advances this mission by funding research; providing comprehensive healthcare services and support to MDA families nationwide; and rallying communities to fight back through advocacy, fundraising, and local engagement.

This FOA invites existing Alzheimer's Disease Patient Registry cooperative agreements that are described in Part 2, Section I to submit revision and or renewal applications. The Alzheimer's Disease (AD) Patient Registry is a population-based longitudinal cohort study of AD and dementia that is linked to an HMO-medical record system or a similar record system. Potential applicants are strongly encouraged to contact their current program officer prior to submission to discuss the application.

DARPA seeks proposals to design, build, demonstrate, and validate a nonsurgical neural interface system to broaden the applicability of neural interfaces to the able-bodied warfighter. The final technology aims to enable neural recording and stimulation with sub-millimeter spatial resolution. See attached BAA package for full details.